Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021671 · ClinicalTrials.gov registry record · Phase 3
Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,720
- Enrollment target
NCT00021671: Completed Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00021671 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,720 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (382% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021671, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,720 participants
- Enrollment target
Study Summary
The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during pregnancy, and the passing of HIV from a mother to her baby has been found. Early treatment of these problems may reduce the risk of passing HIV from an HIV-positive mother to her baby. \[Note: As of 02/21/03, enrollment into this study was halted because preliminary data showed that the study antibiotics were not effective in preventing mother-to-child HIV transmission.\]
Interventions
- DRUG Metronidazole
- DRUG Erythromycin
- DRUG Nevirapine
- DRUG Ampicillin sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,720 participants |
| Est. Completion | 2004-11 |
| Phase | Phase 3 |
What the finished NCT00021671 record still lists
NCT00021671 is an interventional study that assigns participants to a tested intervention. Its 3,720 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (382% higher).
The record links to 0 conditions, and to 4 interventions - of which Metronidazole is the first listed.
NCT00021671 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00021671 about?
NCT00021671 is a clinical study titled "Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission". The purpose of this study is to see if antibiotic drugs given to treat an infection of the uterus during pregnancy can reduce the chances of HIV being passed from an HIV-positive mother to her baby. A link between bacterial disease of the vagina, premature birth, infection of the uterus during preg...
What is the current status of trial NCT00021671?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,720 participants. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00021671?
The interventions under investigation include: Metronidazole (DRUG), Erythromycin (DRUG), Nevirapine (DRUG), Ampicillin sodium (DRUG).
Who is sponsoring clinical trial NCT00021671?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00021671's enrollment target sits among peer trials
3,720 66th of 2000 higher than 1,935 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06076304 · 3,720 participants · Phase 4
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis
- NCT06401863 · 3,691 participants · NA
Shared Decision for Drug Interactions in Oral Anticoagulation
- NCT06172660 · 3,750 participants
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
- NCT06298253 · 3,750 participants · NA
Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2